stockrow
Saturday 7 November 2026
Export STOK’s income statement to Excel — free account
Stoke Therapeutics, Inc.
STOK Healthcare Biotechnology
Stoke Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $184.4 million, up 404.5% from fiscal 2024.
- Revenue
- +5.86%
- EPS
- −65.7%
- Free cash flow
- −114.9%
Quarter to September 2026, against a year earlier
26.54
0.47
+1.80%
Follow STOK
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
63.01 | 78.30 | 64.01 | 10.19 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 41.85 | |
P/Operating CF |
(28.35) | (38.17) | (33.89) | (61.72) | |
P/B ratio |
5.04 | 6.25 | 5.20 | 5.33 | |
Price to Tangible BV |
5.04 | 6.25 | 5.20 | 5.33 | |
EV/Sales |
51.69 | 67.68 | 53.30 | 8.65 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(6.93) | (10.49) | (11.65) | 34.99 | |
EV/FCF |
(6.76) | (10.33) | (11.58) | 35.51 | |
Quick Ratio |
6.72 | 7.19 | 8.57 | 5.06 | |
Current Ratio |
7.24 | 7.69 | 8.99 | 5.28 | |
Net Debt/EBITDA |
4.13 | 4.48 | 6.44 | 4.62 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.07 | 0.07 | 0.08 | 0.53 | |
Operating CF/Net income |
0.85 | 0.92 | 1.21 | 0.53 | |
Capex/Depreciation |
(27.41) | (22.20) | (4.77) | 1.59 | |
Research and Development Expense of Revenue |
531.59% | 530.84% | 636.91% | 2,973.97% | |
Selling, General and Administrative Expense of Revenue |
255.34% | 270.81% | 320.66% | 1,508.27% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
98.03% | 115.84% | 140.52% | 702.43% | |
Graham Net Nets |
0.17 | 0.13 | 0.16 | 0.13 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(14.60%) | (10.30%) | (8.72%) | (0.32%) | |
Free Cash Flow Yield |
(12.14%) | (8.36%) | (7.19%) | 2.39% | |
Revenue per Share |
0.16 | 0.14 | 0.10 | 0.02 | |
Operating CF per Share |
(0.92) | (0.86) | (0.96) | (0.51) | |
Capex per Share |
(0.04) | (0.03) | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.96) | (0.89) | (0.97) | (0.52) | |
Cash per Share |
4.67 | 4.44 | 5.45 | 4.81 | |
Shareholders Equity per Share |
5.16 | 5.23 | 6.26 | 5.95 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.16 | 5.23 | 6.26 | 5.95 | |
Free Cash Flow |
(65.54) | (58.56) | (60.93) | (30.69) | |
Working Capital |
305.44 | 280.61 | 325.88 | 247.83 | |
Capital Expenditures |
(2.85) | (1.98) | (0.35) | (0.23) | |
Net Current Asset Value |
300.31 | 274.12 | 318.28 | 239.72 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.25 | 0.21 | 0.06 | 0.17 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
10.46 | 5.17 | 3.37 | 5.14 | |
Average Payables |
4.95 | 4.55 | 4.51 | 3.72 | |
Average Assets |
383.48 | 389.24 | 425.08 | 344.99 | |
Average Common Equity |
330.35 | 340.25 | 372.48 | 290.74 |
Columns are period end dates · fundamentals updated 5 Nov 2026